
News|Videos|November 16, 2026
Executive Conversations: What Sets Strategic Trade Teams Apart?
In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.
Advertisement
Advertisement
The first episode of Executive Conversations: The Future of Pharmaceutical Commercialization, presented by Pharmaceutical Commerce, closes by asking how a trade organization can be seen not just as operationally excellent, but as a
Related to this article

In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?
Advertisement
Advertisement

